Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
← catalyst calendarNCT06898957 · readout in 1,769 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →. With MediLink.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
29actual
Sites
36
Countries
Canada, China, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-16 | actual | When the study began enrolling |
| Primary completion | 2031-06-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-06-23 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small Cell Lung Cancer
Interventions
- Drug: YL201
- Drug: Tarlatamab
- Drug: Durvalumab
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing Dose-limiting toxicities (DLTs)
measured Up to Day 21
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
measured Up to 3.5 Years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed